Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMRX Immuneering Corp

Trading 06-15 11:31:23 EDT

4.28

+0.09

+2.03%

High4.33	Low4.23	Vol338.68K
Open4.28	D1 Closing4.19	Amplitude2.39%
Mkt Cap276.04M	Tradable Cap232.61M	Total Shares64.57M
T/O1.45M	T/O Rate0.62%	Tradable Shares54.41M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMRX","market":"US","secType":"STK","nameCN":"Immuneering Corp","latestPrice":4.275,"timestamp":1781537482287,"preClose":4.19,"halted":0,"volume":338675,"delay":0,"changeRate":0.02028639618138424,"floatShares":54411779,"shares":64569967,"eps":-1.06,"marketStatus":"Trading","change":0.085,"latestTime":"06-15 11:31:23 EDT","open":4.275,"high":4.325,"low":4.225,"amount":1447514.1208225,"amplitude":0.023866,"askPrice":4.28,"askSize":800,"bidPrice":4.27,"bidSize":549,"shortable":3,"etf":0,"ttmEps":-1.06,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1781553600000},"marketStatusCode":2,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":4.19,"preHourTrading":{"tag":"盘前","latestPrice":4.23,"preClose":4.19,"latestTime":"09:25 EDT","volume":489,"amount":2062.2715826999997,"timestamp":1781529947467,"change":0.04,"changeRate":0.009547,"amplitude":0.0358},"postHourTrading":{"tag":"盘后","latestPrice":4.13,"preClose":4.19,"latestTime":"19:38 EDT","volume":185,"amount":767.8556,"timestamp":1781307509050,"change":-0.06,"changeRate":-0.01432,"amplitude":0.01432},"volumeRatio":0.64654,"impliedVol":2.3962,"impliedVolPercentile":0.9489},"requestUrl":"/m/hq/s/IMRX/tweets","defaultTab":"tweets","newsList":[{"id":"2643205782","title":"Immuneering Names Andrew Gengos as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2643205782","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643205782?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:58","pubTimestamp":1781528307,"startTime":"0","endTime":"0","summary":"Immuneering  has named Andrew Gengos as chief financial officer, starting July 16, the company said Monday.Gengos most recently served as CFO and head of corporate development at Terns Pharmaceuticals, the company said.He previously served as CFO and chief business officer of Athira Pharma, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4563","BK4139","IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643082002","title":"Immuneering Names Andrew Gengos Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643082002","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643082002?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:53","pubTimestamp":1781524380,"startTime":"0","endTime":"0","summary":"Immuneering has hired Andrew Gengos as the late-stage clinical oncology company's new chief financial officer.Immuneering on Monday said Gengos most recently served as finance chief and head of corporate development at Terns Pharmaceuticals, which Merck & Co. acquired last month.Mallory Morales, Immuneering's senior vice president of finance, chief accounting officer and treasurer, has been serving as the Cambridge, Mass., company's principal financial and accounting officer.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4139","IMRX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643083122","title":"Immuneering - Appoints Andrew Gengos as Chief Financial Officer Effective July 16, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643083122","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643083122?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:30","pubTimestamp":1781523001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA5VT9QB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMRX","BK4539","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643520833","title":"Press Release: Immuneering Appoints Andrew Gengos as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643520833","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643520833?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:30","pubTimestamp":1781523000,"startTime":"0","endTime":"0","summary":"- Former CFO of Terns Pharmaceuticals to join Immuneering -. \"Andrew is a proven biotechnology executive with a strong track record of helping innovative companies navigate critical stages of growth and value creation,\" said Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering. \"His experience as a CFO, business development leader, and strategic advisor will be invaluable as we advance our clinical programs and prepare for the next phase of Immuneering's growth. We are delighted to welcome Andrew to our leadership team.\". \"I am thrilled to join Immuneering at such an exciting time in the company's development,\" said Andrew Gengos. \"Atebimetinib is now a Phase 3 candidate in first-line pancreatic cancer, supported by recently presented survival and tolerability data that are highly encouraging in a disease where new treatment options are urgently needed. A growing body of data supports the potential of Immuneering's differentiated deep cyclic inhibitor technology to","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","IMRX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642423703","title":"Immuneering Shareholders Approve Directors and Auditor at Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642423703","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642423703?lang=en_us&edition=fundamental","pubTime":"2026-06-12 06:58","pubTimestamp":1781218732,"startTime":"0","endTime":"0","summary":"Immuneering ( ($IMRX) ) has shared an update. Immuneering Corporation held its Annual Meeting of Stockholders on June 11, 2026, with 44,495,059 Cla...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immuneering-shareholders-approve-directors-and-auditor-at-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immuneering-shareholders-approve-directors-and-auditor-at-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMRX","BK4563","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642341284","title":"Immuneering's Phase 3 Trial of Atebimetinib Plus mGnP to Treat Pancreatic Cancer Doses First Patient","url":"https://stock-news.laohu8.com/highlight/detail?id=2642341284","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642341284?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:24","pubTimestamp":1781180654,"startTime":"0","endTime":"0","summary":"Immuneering  said Thursday that the first patient has been dosed in a phase 3 trial of atebimetinib plus modified gemcitabine/nab-paclitaxel to treat pancreatic cancer.The oncology company said the trial is evaluating the safety and efficacy of atebimetinib + mGnP in patients with metastatic pancreatic ductal adenocarcinoma who have received no prior systemic anti-cancer therapy.Chief Executive Ben Zeskind said in a statement that the company intends to initiate more sites and dose more patients, and that topline data are expected in mid-2028.Shares of Immuneering were up 3.4% pre-bell.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMRX","BK4563","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642289490","title":"Immuneering doses first patient in Phase 3 MAPKeeper 301 trial for first-line metastatic pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2642289490","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642289490?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:33","pubTimestamp":1781177629,"startTime":"0","endTime":"0","summary":"Immuneering dosed the first patient in MAPKeeper 301, a global pivotal Phase 3 trial in first-line metastatic pancreatic cancer.The study tests atebimetinib with modified gemcitabine and nab-paclitaxel versus standard gemcitabine and nab-paclitaxel alone.Earlier survival and tolerability results were presented this year, supporting the move into a registrational trial.Topline Phase 3 results, including overall survival, are expected in mid-2028.The readout will guide whether atebimetinib can support a new first-line option in a high-need market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the inform","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDLb9JttN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","IMRX","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642289148","title":"Immuneering - Topline Data From Phase 3 Trial Expected in Mid-2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2642289148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642289148?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:30","pubTimestamp":1781177400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA16QSGN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","IMRX","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640103759","title":"Immuneering Buy Rating Reaffirmed as Analyst Sees ASCO Sell-Off as Overdone; $11 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2640103759","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640103759?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:37","pubTimestamp":1780400229,"startTime":"0","endTime":"0","summary":"Immuneering, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia from Needham maintained a Buy rating on...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/immuneering-buy-rating-reaffirmed-as-analyst-sees-asco-sell-off-as-overdone-11-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/immuneering-buy-rating-reaffirmed-as-analyst-sees-asco-sell-off-as-overdone-11-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640960255","title":"Immuneering Advances Atebimetinib With Positive Phase 2a Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2640960255","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640960255?lang=en_us&edition=fundamental","pubTime":"2026-06-02 06:49","pubTimestamp":1780354197,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Immuneering ( ($IMRX) ). On June 1, 2026, Immuneering reported updated Phase 2a data for atebimetinib, a once-d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immuneering-advances-atebimetinib-with-positive-phase-2a-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immuneering-advances-atebimetinib-with-positive-phase-2a-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IMRX","BK4563","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640962173","title":"Immuneering - 17.3 Month Median Overall Survival Observed in 320 Mg ITT Population as of April 24, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2640962173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640962173?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:52","pubTimestamp":1780347175,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nFWN4290J3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","IMRX","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640296214","title":"Immuneering - Announces Updated Phase 2a Data for Atebimetinib in Pancreatic Cancer - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2640296214","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640296214?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:52","pubTimestamp":1780347175,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nFWN4290J3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMRX","BK4563","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640956718","title":"Immuneering says atebimetinib plus chemo posts 17.3-month median survival in Phase 2a first-line pancreatic cancer study","url":"https://stock-news.laohu8.com/highlight/detail?id=2640956718","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640956718?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:35","pubTimestamp":1780313738,"startTime":"0","endTime":"0","summary":"Immuneering highlighted Phase 2a results already presented at the 2026 ASCO meeting for atebimetinib with chemotherapy in first-line metastatic pancreatic cancer.Patients lived longer than historical outcomes on standard chemotherapy, with responses consistent across cohorts despite different follow-up durations.The regimen showed favorable tolerability, with severe treatment-related side effects largely tied to chemotherapy rather than atebimetinib.A global Phase 3 MAPKeeper 301 trial is recruiting, with first patient dosing expected in mid-2026 to confirm the survival benefit.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief on June 01, 2026, and is","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDLbymZrg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4139","BK4563","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640804959","title":"Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2640804959","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640804959?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:30","pubTimestamp":1780313400,"startTime":"0","endTime":"0","summary":"- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study - - Only two categories of Grade 3+ treat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304230/0/en/Immuneering-Presents-Compelling-17-3-Month-Median-Overall-Survival-and-Favorable-Tolerability-with-Atebimetinib-Chemotherapy-in-First-Line-Pancreatic-Cancer-Patients-at-ASCO.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4139","ORR","BK4539","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637365292","title":"Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and Cencora (COR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637365292","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637365292?lang=en_us&edition=fundamental","pubTime":"2026-05-22 08:40","pubTimestamp":1779410407,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immuneering (IMRX) and Cencora (COR). Immuneering (IMRX) In a rep...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-immuneering-imrx-and-cencora-cor-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-immuneering-imrx-and-cencora-cor-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0289739699.SGD","LU1430594728.SGD","LU2237957811.SGD","XBI","BK4137","BK4581","LU1084165304.USD","BK4139","LU0029874061.USD","XLV","BK4529","LU0128526141.USD","IMRX","COR","BK4585","BK4588","BK4175","LU1585245621.USD","BK4084","LU1261432733.SGD","BK4563","HCSG","BK4539","LU1814569148.SGD","SG9999004303.SGD","LU2237957902.USD","SGXZ23171101.USD","LABU","LU0058720904.USD","LU2324357040.USD","LU1119994496.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637352099","title":"Immuneering says atebimetinib-chemo trial shows 17.3-month median survival in pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2637352099","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637352099?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:02","pubTimestamp":1779397368,"startTime":"0","endTime":"0","summary":"Immuneering reported updated Phase 2a results for atebimetinib with chemotherapy in first-line metastatic pancreatic cancer, with full data slated for an oral presentation at the ASCO Annual Meeting on June 1, 2026.The update pointed to longer survival with manageable tolerability, with severe treatment-related side effects largely attributed to chemotherapy rather than the investigational drug.The readout supports the company’s planned randomized Phase 3 MAPKeeper 301 trial, which is recruiting with a first patient dosing targeted for mid-2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the informa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL8m1NqH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4139","BK4539","IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637527563","title":"Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated With Atebimetinib Plus Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2637527563","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637527563?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:00","pubTimestamp":1779397201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA2BPV9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMRX","BK4563","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637369357","title":"Immuneering Corp - Only Anemia (16%) and Neutropenia (18%) Grade 3+ Adverse Events in ≥10% of Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2637369357","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637369357?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:00","pubTimestamp":1779397201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA2BPV9:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMRX","BK4539","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357380","title":"Immuneering Corp - Full Data From 55 Patients to Be Presented at Asco on June 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357380","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357380?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:00","pubTimestamp":1779397201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA2BPV9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","IMRX","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357336","title":"Immuneering Corp - Reports 17.3-Month Median Overall Survival as of April 24, 2026 Data Cutoff","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357336","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357336?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:00","pubTimestamp":1779397201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA2BPV9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","IMRX","BK4563"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immuneering.com","stockEarnings":[{"period":"1week","weight":-0.0187},{"period":"1month","weight":-0.2212},{"period":"3month","weight":-0.1703},{"period":"6month","weight":-0.3109},{"period":"1year","weight":1.1378},{"period":"ytd","weight":-0.3632}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.22671},{"month":2,"riseRate":0.6,"avgChangeRate":-0.02029},{"month":3,"riseRate":0.4,"avgChangeRate":0.059054},{"month":4,"riseRate":0.2,"avgChangeRate":-0.166499},{"month":5,"riseRate":0.4,"avgChangeRate":0.024846},{"month":6,"riseRate":0.6,"avgChangeRate":0.226754},{"month":7,"riseRate":0.75,"avgChangeRate":0.027683},{"month":8,"riseRate":0.4,"avgChangeRate":0.157517},{"month":9,"riseRate":0.8,"avgChangeRate":0.592866},{"month":10,"riseRate":0.2,"avgChangeRate":-0.073665},{"month":11,"riseRate":0.4,"avgChangeRate":-0.104912},{"month":12,"riseRate":0.4,"avgChangeRate":-0.101218}],"exchange":"NASDAQ","name":"Immuneering Corp","nameEN":"Immuneering Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immuneering Corp,IMRX,Immuneering Corp股票,Immuneering Corp股票老虎,Immuneering Corp股票老虎国际,Immuneering Corp行情,Immuneering Corp股票行情,Immuneering Corp股价,Immuneering Corp股市,Immuneering Corp股票价格,Immuneering Corp股票交易,Immuneering Corp股票购买,Immuneering Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction